MedPageToday Lengthy viral antigen persistence far more common, regardless of prior vaccination. Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.
Tests for 40% of SARDs patients remained positive for at least one SARS-CoV-2 antigen 3 months after infection in one prospectively assembled cohort, compared with 17.5% of COVID-19 patients without SARDs from a separate prospective study, according to Naomi Patel, MD, MPH, of the Mass General Brigham health system in Boston, and colleagues.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.